NEW YORK, April 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding FLIR Systems, Inc. (NASDAQ: FLIR), Itron, Inc. (NASDAQ: ITRI), Garmin Ltd. (NASDAQ: GRMN), FEI Company (NASDAQ: FEIC) and Cepheid (NASDAQ: CPHD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1805-100free.
FLIR Systems, Inc. Analyst Notes
On April 25, 2014, FLIR Systems, Inc. (FLIR) reported its Q1 2014 financial results. The Company's revenue was up 0.8% YoY to $351.5 million. Net income was $29.9 million, or $0.21 per diluted share, compared to $51.6 million, or $0.35 per diluted share, in Q1 2013. Andy Teich, President and CEO of FLIR said, "Our first quarter results were in-line with our expectations. Healthy growth in our commercial-oriented markets was offset by declines in government-funded sectors. We continued executing on our realignment plan, which we believe will be a valuable investment for our long-term performance, We expect continued improvement as we move throughout this year and are excited about our product pipeline that is enabled by our new Lepton core." For full-year 2014, the Company reaffirmed its guidance and expects revenue to be between $1.45 billion to $1.55 billion. The full analyst notes on FLIR are available to download free of charge at:
Itron, Inc. Analyst Notes
On April 24, 2014, Itron, Inc. (Itron) announced that the Mitsubishi Electric Corporation (MELCO) will deploy Itron's smart grid software for a major smart metering project with Chubu Electric Power Company (Chubu Electric) in Japan. The Company informed that its OpenWay Collection Engine software will be installed at Chubu Electric to securely collect and relay a high-volume of data from field routers and approximately 10 million smart meters and deliver the data to the utility's meter data management system. "This unique deployment at Chubu Electric demonstrates the true flexibility and interoperability of Itron's OpenWay platform, which can adapt to meet various utility needs and deployment configurations. We are pleased to collaborate with the Mitsubishi Electric Corporation to bring a complete smart metering solution to Japan," said Alan White, Itron Vice President of sales, marketing and delivery for Electricity in the Asia-Pacific. The full analyst notes on Itron are available to download free of charge at:
Garmin Ltd. Analyst Notes
On April 17, 2014, Garmin Ltd. (Garmin) announced the latest update to the Garmin Pilot app for Android. According to the Company, the update will provide interactive features for easier navigation and chart-reading throughout a pilot's flight. The Company informed that new features include track-up orientation, faster map rendering, higher resolution at tighter zoom levels, and SafeTaxi integration on the moving map display. Garmin stated that the latest version of Garmin Pilot app is available as a free update to existing Android customers. The full analyst notes on Garmin are available to download free of charge at:
FEI Company Analyst Notes
On April 14, 2014, FEI Company (FEI) announced that it will be participating at the Bank of America Merrill Lynch Health Care Conference. The Company informed that its Executive Vice President & CFO, Ray Link, is scheduled to present on Tuesday May 13, 2014 at 8:40 a.m. PDT, in Las Vegas, NeVada. The full analyst notes on FEI are available to download free of charge at:
Cepheid Analyst Notes
On April 17, 2014, Cepheid reported its Q1 2014 financial results. The Company's revenues increased 16.3% YoY to $106.9 million. Q1 2014 net loss was $9.3 million compared to a net income of $0.3 million in Q1 2013. "We placed an additional 503 GeneXpert systems globally in the first quarter of 2014, contributing to 26% growth in our clinical business, and bringing our cumulative installed base to more than 6,000," said John Bishop, Cepheid's Chairman and CEO " With the recent additions of Xpert HPV and Xpert Norovirus to our test menu outside the US, we are entering a prolific, global product cycle that will further extend the portfolio of accurate, fast and easy-to-use molecular diagnostics available to our customers." For full-year 2014, Cepheid expects total revenue to be between $446.0 million to $461.0 million, and net loss in the range of $0.43 to $0.38 per share. The full analyst notes on Cepheid are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review